As of now I do not see any bullish chart formations in PEL. The technical set up also is not too encouraging, the stock price being well below 200 dema in the midst of a strong rally in overall markets…
@Surender I do not track Novartis. Its leading products are well known but in pharma business, which is highly fragmented in India, well known brand names does not provide too much of an edge. Another company can come up with a copy cat product at much reduced prices and in India where a large part of patient population is non affording, this fact assumes a lot of significance. You can check prices of tegrital and mazetol both of which contain same molecule. Tegrital is the original molecule but because of very big price difference between it and other clones, doctors would prefer to prescribe cheaper alternatives to provide lower cost drugs to patients.
@Rafi_Syed How to analyse a pharma company is something beyond the scope of this thread. You will have to read up annual reports of companies which give out detailed information. Or else go through relevant pharma threads on VP. I recall @ankitgupta gave a presentation on one of our Goa VP conferences on pharma sector. You can try to locate his presentation and go through it.
@ram1984 I don’t track deepak fertiliser.
@Abhishek_Kumar_9 I haven’t looked at DP wire.
| Subscribe To Our Free Newsletter |
